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Abstract 
The clinical symptoms and MRI characteristics of transverse myelopathy (TM) due to 
non- compressive causes  are reviewed, with special emphasis on the differential 
diagnosis between inflammatory demyelinating  lesions, and metabolic and vascular 
myelopathies. Inflammatory transverse myelopathies are the commonest and most 
difficult ones to identify. The differentiation between clinically isolated syndromes, 
multiple sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis  and  
metabolic causes is based on both clinical symptoms and paraclinical signs including 
magnetic resonance imaging, cerebrospinal fluid analysis, and immunologic and 
biochemical parameters. The most intriguing form of TM is that where there is clinical 
evidence of complete spinal cord transection, with normal findings in magnetic resonance 
imaging in the acute phase,  but subsequent cord atrophy.  
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Introduction 
 
The clinical symptoms of complete or incomplete  transverse myelopathy  (TM) indicate 
the presence of a lesion of the spinal cord in need of urgent therapy. However, the exact 
diagnosis is often complicated  by extensive differential diagnosis (1,2,3,). Transverse 
myelopathies may result from pathogeneticaly heterogeneous disorders of the spinal cord. 
Although  they are most commonly inflammatory in origin, including autoimmune 
disorders such as systemic lupus erythematosus (4), Sjögren's syndrome (5,6), 
antiphospholipid antibody syndrome (7), mixed connective tissue disease (8), systemic 
sclerosis (9), ankylosing spondylitis (10) and sarcoidosis (11), vascular and metabolic 
causes are more common than usually suspected.  TM can also result from different 
bacterial or viral infections (12-16).   
In addition to its rapid clinical development, clues to the exact diagnosis of TM will be 
obtained from cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI), 
neurophysiological features and  immunological studies. Spinal cord MRI is very 
important in order to exclude compressive lesions of the spinal cord (17,18,19). 
Inflammatory lesions often produce local enlargement of the spinal cord and increased 
signal intensity on T2 weighted sequences of MRI (17).  However, in some cases it is 
difficult to differentiate inflammatory lesions from intramedullary tumors, compressive 
spinal cord diseases (17,18,19), hematomas, and ischemic events. CSF study  is mostly 
useful in identifying bacterial and viral infections; biochemical parameters such as 
deficiencies of vitamins E and B12, and serum copper levels can rule out  other metabolic 
etiologies of  myelopathy.   
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Inflammatory myelopathies 
Inflammation is not only the commonest basis of TM but is also the most difficult to 
differentiate.  The majority of incomplete TM in young persons are diagnosed as multiple 
sclerosis (MS) (20,21,22)  or clinically isolated syndrome (CIS) . This was the case in our 
previous study where 31 patients with TM: six cases were originally called  CIS ,who all 
later converted to MS (2). The clinical symptoms in CIS are characterized by dominant 
and asymmetrical sensory signs and symptoms, mostly paraesthesias, usually slowly 
spreading from the legs to the upper part of the body, more pronounced on one side, often 
with a band-like sensation or pressure around the abdomen or chest. MRI is also quite 
typical with small demyelinating lesions, involving less than two segments, most often 
located in the posterior or lateral part of the spinal cord (22,23) (Fig 1). Patients with MS 
commonly also have demyelinating lesions of the brain, while in CIS, spinal lesions are 
the only sign of  disease (Fig  1,2 ). There is a small group  of patients with isolated 
spinal cord demyelination and typical relapsing course for many years, sometimes called 
spinal MS. In MS, and often in CIS oligoclonal bands (OCB) are present in the CSF.   
Even in fulminating MS,  MRI  of the spinal cord is most typical, although brain MRI 
may point to other differential diagnosis, eg to DEM or granulomatous demyelination as 
it is seen in presented case ( Fig 3).   
Another diagnostic problem is posed by patients with, more or less symmetrical TM and 
with long hyperintense MRI lesions, involving three or more segments of the spinal cord, 
the so-called longitudinal extensive transverse myelitis (LETM). The TM may be 
associated with optic neuritis.  Nowadays such patients are designated as part of the  
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neuromyelitis optica (NMO) spectrum (24). The differential diagnosis of patients with 
LETM is quite complex. The typical NMO consists of a LETM, occupying the central 
gray matter in the acute stage (24, 25). The symptoms are rarely monophasic, more often 
aggressively relapsing , limited  to the optic nerve and spinal cord, mostly sparing  the 
brain (25-27). For a long time NMO was regarded as an MS variant, although the clinical 
symptoms  were different. ON in NMO tends to be more severe and leaves a more severe 
visual impairment compared to attacks of ON in the context of MS, although  the clinical 
presentation of ON in both diseases is similar. Spinal cord relapses typically consist of a 
complete TM myelitis with bilateral motor weakness, a sensory level, sphincter 
dysfunction, prominent dysesthetic and even radicular pain. Brain stem involvement can 
occur, usually as an extension of a severe cervical myelitis, and may cause hiccups, 
intractable nausea, or respiratory failure (26,28). Paroxysmal tonic spasms are more 
common in NMO compared with prototypic MS. This characteristic symptom of 
demyelination is believed to represent ephaptic transmission across demyelinated axons 
(27,29).  The finding that  some cases of NMO are associated with a highly specific 
serum autoantibody marker aquaporin-4 antibody, also known as the “NMO-IgG,” makes 
possible to differentiate NMO from MS (27-29). Specific serum autoantibody marker 
(NMO-IgG) against aquaporin 4 derived from peripheral B cells cause the activation of 
complement, inflammatory demyelination and necrosis typical for NMO (Fig 4). Whether 
NMO-IgG titers correlate with disease and  attack severity or favorable response to 
therapy is unknown (30). As NMO-IgG can be detected at the first attack of myelitis or 
ON, this suggest that the antibody is more likely an integral part of the pathogenesis of 
the disease rather than an epiphenomenon of the tissue injury (27,29,30). In seropositive 
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patients who are presented  with typical or limited  clinical symptoms of NMO, 
immediate treatment  with corticosteroids or plasmapheresis in  more serious clinical 
presentation is necessary (31). Patients also need preventive treatment with azathioprine 
or mycophenolate mofetil. Seronegative patients with clinical symptoms of NMO (Fig 4) 
should be treated in the same manner (31). While in our previous study three patients out 
of 31 presented with seronegative NMO, in recent years  new 3 seropositive patients were 
identified. NMO antibodies are very important in  the diagnosis  of other  patients with  
LETM. However around 30% of patients presenting with NMO symptoms are NMO 
negative (Fig 5).On the other hand, there are several reports of seropositivity in patients 
with  classical MS  (32). 
In some instances, severe clinical symptoms, like tetraparesis or respiratory insufficiency, 
should raise suspition  for NMO (fig 6) despite the absence of the specific LETM lesion 
on MRI.  
 
Neuromyelitis optica and autoimmune diseases  
LETM or NMO or both  are known complications of systemic lupus erythematosus 
(SLE) or Sjögren's syndrome (SS) although some  patients may lack sufficient clinical 
manifestations for their formal diagnosis(33-35). A pathophysiological link between SLE 
and NMO has not yet been established, although some authors have suggested a role for 
lupus anticoagulant, and antinuclear antibody (ANA) in the development of CNS lesions.  
Approximately half  the patients with  NMO and connective  tissue disorders are 
seropositive for NMO-IgG, whereas patients with SLE or SS who do not have 
manifestations of NMO are uniformly seronegative (35) (Fig 7). It is likely that these 
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patients have two coexisting autoimmune disorders rather than a vasculitic complication 
of a systemic autoimmune disease such as SLE or SS  (35, 36). Similarly, NMO may 
coexist with myasthenia gravis or other systemic autoimmune diseases (37, 38) (Fig 8). 
 
Parainfectious  or postinfectious TM are not rare although the triggering infectious agent 
is identified in only very few patients (39,40). Parainfectious or postvaccinal 
demyelinating  disorders of the CNS are  characterized  by signs of encephalopathy, 
meningismus and  multifocal signs of  CNS  dysfunctions, and are diagnosed as acute 
disseminated encephalomyelitis (ADEM (39,40). Brain MRI reveals multiple medium-
sized or large white matter lesions,  also involving the deep grey matter as well as cortical 
structures (39-42). ADEM may also present as isolated LETM (Fig 9). The selective 
involvement of  the posterior columnes is, in a way, similar to what is seen in NMO. It 
suggest that these parts of the CNS are immunologically more vulnerable (39-42). 
Previous respiratory infection, and mild , monophasic course of the disease of this 
particular patient point to the diagnosis of ADEM and against NMO.  In our previous 
study of TM, 11  of 31 patients were diagnosed as DEM.  
 
Recently, gadolinium enhancement (GDE) was explained as a diagnostic  parameter that 
may help in differentiating between ADEM and  NMO (43,44). The former, without 
lesion enhancement in MRI  may represent a manifestation of NMO. The lack of 
enhancement suggests an intact blood-brain barrier and supports a unique mechanism of 
edema induction due to dysfunction of water channels (43). But in  some cases, especially 
in cases with a subacute course,  spinal cord  demyelination is  not followed by  GDE 
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enhancement(40,41).  In such patients right diagnosis is based on follow up , especially in 
patients without LEMT. Some of these patients (Fig 10)  in the  future  will  develop  MS.  
A different diagnostic problem is encountered in patients who develop a complete 
transverse spinal syndrome without signs of demyelination or other abnormalities  of the 
spinal cord in MRI. Two such patients were young women. One developed pain in the 
back after swiming and  within a  few minutes developed severe flaccid paraparesis and 
urinary incontinence. Brain and entire spinal cord MRI were normal. After  a month she 
developed severe  spastic paraparesis, and her spinal MRI showed only atrophic changes. 
The  neurologic deficit had remained unchanged.  Similar symptoms  developed in 
another young woman, with the sudden onset of paraplegia, urinary incontinence and a 
sensory level below T9. Spinal and brain MRI were normal.  After a few months she still 
had severe spastic paraparesis with  the same sensory level below T9  and atrophy in 
T10-T11  was identified  in spinal  cord MRI. 
In  our  previous study  four of our 31 patients had  the similar osent symptoms and 
clinical course. (2)  
Analysis of the CSF in these patients with normal spinal MRI, demonstrated the presence 
of  OCB or elevated protein levels, but no vigorous inflammatory reaction, along with the 
lack of demyelination, suggest that parenchymatous neurons are the sites of the 
pathologic involvement, and are are analogous to the acute lesions of axonal 
polyneuropathy. Such cases  
could be variants of DEM although similar cases were described in patient with SLE and 
was regarded as part of NMO spectrum (45). It was found that  about 40% of acute 
transverse myelopathies cannot be documented by MRI (17) 
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Metabolic myelopathies 
Metabolic myelopathies most commonly occur in patients with vitamin  B12 
(cyanocobalamin) (Fig. 11), copper (Cu) and  vitamin E  deficiencies (46,47). The 
neurological manifestations may be the earliest and not infrequently the only signs of 
B12 deficiency. They may have a relatively sudden onset, that include spastic 
paraparesis, impaired perception of joint position and vibration, commonly involving the 
hands (Fig 11). The myelopathy may be associated with neuropathy, cognitive 
impairment and paraesthesias. MRI of the spinal cord typically shows hyperintensive 
changes, mainly involving the posterior and lateral columns (46).  Contrast enhancement 
may be present. Cu defiency is caused by low serum copper  due to malabsorbtion, 
gastric surgery, or  excessive zinc consumption. The clinical symptoms are characterized  
by myelopathy that resembles subacute combined degeneration seen in B12 defiency. 
MRI similarly shows increased signal involving the dorsal and lateral column (47). 
Vascular myelopathies 
Vascular myelopathies may arise from haemorrhage, infarction , a vascular 'steal“ 
syndrome, or venous congestion (48). Spinal ischaemia  may be due to vasculitis 
(polyarteritis nodosa, Behcet disease, giant cell arteritis), systemic hypoperfusion (in 
cardiac arrest, aortic rupture, aortic dissecon or coarctation), embolism (atrial myxoma, 
mitral disease, endocarditis, fibrocartilaginous emboli from a ruputured intervetebraldisc) 
and  infectious  causes (syphylitic arteritis, bacterial meningitis ) (48,49). The symptoms 
of spinal cord ishaemia are often stuttering or stepwise, and not necessarily maximal at 
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onset. The clinical symptom may include spastic paraparesis or tetraparesis, dissociation 
of  sensation, and perseveration of proprioception  that are typical for  vascular lesions  of 
the spinal cord. MRI in vascular TM is characterized  by pencil-like lesions in  the anteior 
part of the spinal cord with typical   hypodense and  hyperintense  long lesions  (Fig 12). 
Diffuse weight imaging (DWI) is promising but mostly not helpful. 
 
Conclusion 
The differential diagnosis of TM is  complex due to the heterogeneity of   the 
pathological  processes. In MS, the most  common inflammatory  disorder of the spinal 
cord, the differential diagnosis  is relatively simple. Differentiation of NMO, especially 
of the NMO spectrum is more difficult, and it is especially important to differentiate 
seronegative NMO from DEM. Spinal cord DEM is remarkably similar in many aspects 
to NMO. Differentiation according to GDE is unreliable.  
It has been suggested that patients with multifocal lesions in the spinal cord, 
demyelinating lesions in the brain and optic nerves, OCB in the CSF and clinical or 
laboratory evidence of systemic autoimmune disorder are at  greater risk of recurrence of  
TM. A special problem is the patient with  symmetrical spastic paraparesis or 
tetraparesis, but without  hyperintensive  or other lesions in spinal cord MR, who 
subsequently develop severe cord atrophy.  
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Figures 
Figure 1.  A young man with clinical symptoms of incomplete TM. MRI showed 
demyelinating lesion of spinal cord, extending less than two segments; brain MRI  
showed typical periventricular lesions characteristic for MS. 
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Figure 2. Patient with CIS presenting clinically with incomplete TM, positive OCB . 
Spinal cord MRI shows hyperintense lesion involving less than two segments. Brain MRI 
was normal. Immunological work-up was normal. Three month later she developed optic 
neuritis. A year later new T2  supratentorial lesions developed.  Diagnopsis: CIS evolving 
to clinically definitive MS 
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Figure 3. Patient with severe relapsing remitting course of MS, died in two years from 
onset. Spinal cord MRI showed typical small posterior  demyelinating lesions, not 
extending over the entire diameter of the spinal cord. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
20 
20 
Figure 4. Patient was admitted blind and with  spastic paraparesis. Spinal cord MRI 
showed long extensive lesion, Brain MRI was normal except for hyperintense lesion of 
optic nerves. NMO antibodies were positive. She was treated with plasmapharesis with 
good recovery of sight and motor functions. She currently taking azathioprine to prevent 
recurrences. 
 
 
 
 
 
 
 
 
  
21 
21 
Figure 5. A 34 year  old woman had the onset of optic neuritis that resolved with  
corticosteroid therapy. Soon after, she had a series of relapses with incomplete, and 
finally complete paraparesis. The disease was temporarily stopped after plasmapheresis, 
but soon started again and patient died two years after onset of  the disease. MRI showed 
LETM demyelination in T2 images, and  extensive destruction in T1 images. 
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Figure 6. A 9-year-old boy suddenly developed flaccid tetraparesis with respiratory 
insufficiency and refractory hiccups. MRI showed LETM  in the anterior part of the cord.  
CSF was normal, OCB were negative, biochemical  parameters and immunological work 
up were  unremarkable. After  corticosteroid treatment and plasmapheresis he was better, 
there was no more need for ventilation, and he was partially able  to move his extremities.  
LEMT with respiratory insufficiency, as well as brain MRI findings pointed to the 
diagnosis of NMO. 
 
  
23 
23 
Figure 7. Patient with lupus and development of spastic pararesis.  MRI showed LETM 
of the spinal cord. NMO antibodies were negative. 
 
Figure 8. Patient with congenital myasthenia and development of spastic paraparesis due 
to LETM lesion of the spinal cord. Immunological work up as well as biochemical 
parameters  were normal. NMO antibodies were negative. 
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Figure 9.  Patient with  monophasic course of disease characterized with paraesthesia in 
arms and loss of vibratory sensation. MRI showed selective involvement of posterior 
columns  Good response to corticosteroid therapy  (presented in the spectrum of DEM). 
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Figure 10. A young woman developed symptoms  of paraesthesia in both legs  First MRI 
performed in 2003  was diagnosed as spinal tumor, and she was scheduled for operation,  
but a second MRI showed regression of the lesion. A year later the lesion was smaller, 
and at the end of 2005 it had completely disappeared. Patient has had no new lesions or 
clinical symptoms since. 
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Figure 11. A woman born in 1953, a strict vegetarian, presented with spastic paraparesis 
and proprioceptive sensory impairment due to LETM in the  posterior colums due to 
cyacobolamin deficiency. CSF was normal. Brain MRI normal.     
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Figure 12. Pencil like  hyperintense lesion in anterior part of spinal cord due to infarction. 
Characteristic  hyperintense and hypointense lesions are seen.  
The patient presented with the sudden development of severe  flaccid tetraparesis and 
respiratory insufficiency.  After one month he was reffered in our  department. 
Neurological examination revealed  flaccid paraparesis of upper extremities and  spastic 
lower  paraparesis with  incontinence. The MRI lesions of patients with ischemic 
myelopathy are discontinuous, partially hyperintense and partially hypointense in T2- 
weighted images as it is seen in this patient. 
 
